Sullam P M, Täuber M G, Hackbarth C J, Sande M A
Antimicrob Agents Chemother. 1985 Feb;27(2):224-6. doi: 10.1128/AAC.27.2.224.
The in vitro activity of gentamicin was compared with its therapeutic efficacy in rabbits with Streptococcus faecalis endocarditis. The test strain was resistant to gentamicin as measured by MICs and MBCs determined in Mueller-Hinton broth alone or in broth supplemented with 50% rabbit serum. Gentamicin also failed to manifest anti-enterococcal activity when evaluated by time-kill studies in broth. However, the addition of serum to the medium did enhance the activity of gentamicin. In the therapy of experimental endocarditis, gentamicin used alone demonstrated anti-enterococcal activity equivalent to that of ampicillin used alone. Vegetation titers in animals treated with gentamicin alone were lower than those of untreated controls (P less than 0.01) and comparable to those in animals treated with ampicillin alone. Thus, gentamicin demonstrated anti-enterococcal activity in vivo despite the resistance observed in vitro, as measured by conventional assays to determine MICs and MBCs.
将庆大霉素的体外活性与其对粪肠球菌性心内膜炎家兔的治疗效果进行了比较。通过在单独的 Mueller-Hinton 肉汤或添加 50%兔血清的肉汤中测定的 MIC 和 MBC 来衡量,测试菌株对庆大霉素耐药。通过肉汤中的时间杀菌研究评估时,庆大霉素也未表现出抗肠球菌活性。然而,向培养基中添加血清确实增强了庆大霉素的活性。在实验性心内膜炎的治疗中,单独使用庆大霉素显示出与单独使用氨苄西林相当的抗肠球菌活性。单独用庆大霉素治疗的动物的赘生物滴度低于未治疗的对照组(P 小于 0.01),且与单独用氨苄西林治疗的动物的滴度相当。因此,尽管通过常规测定 MIC 和 MBC 的方法在体外观察到耐药性,但庆大霉素在体内仍显示出抗肠球菌活性。